Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. by Viswanathan GN et al.
 Newcastle University ePrints 
 
Viswanathan GN, Marshall SM, Balasubramaniam K, Badimon JJ, Zaman AG. 
Differences in thrombus structure and kinetics in patients with type 2 
diabetes mellitus after non ST elevation acute coronary syndrome. 
Thrombosis Research 2014, 133(5), 880-885. 
 
 
Copyright: © 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the 
CC BY-NC-ND license. 
DOI link for article: http://dx.doi.org/10.1016/j.thromres.2014.01.033 
Date deposited:  4th July 2014 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Regular Article
Differences in thrombus structure and kinetics in patients with type 2
diabetes mellitus after non ST elevation acute coronary syndrome
Girish N. Viswanathan a,1, Sally M. Marshall a,2, Karthik Balasubramaniam a,3,
Juan J. Badimon b,4, Azfar G. Zaman a,c,⁎
a Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
b The Mount Sinai School of Medicine, NY, USA
c Freeman Hospital, Newcastle upon Tyne, UK
a b s t r a c ta r t i c l e i n f o
Article history:
Received 16 October 2013
Received in revised form 27 December 2013
Accepted 27 January 2014
Available online 1 February 2014
Keywords:
Whole blood thrombus
Type 2 diabetes mellitus
Non ST elevation acute coronary syndrome
Thrombus kinetics
Antiplatelet therapy
Fibrin structure
Introduction: Despite optimal secondary prevention therapy following non-ST elevation acute coronary syn-
drome (NSTE-ACS), recurrent thrombotic events are more frequent in patients with type 2 diabetes mellitus
(T2DM).
Materials and Methods: This exploratory study was aimed to evaluate quantitative and qualitative aspects of
thrombus. In 28 patients with and without T2DM treated with aspirin and clopidogrel we assessed thrombus
quantity using an ex-vivo chamber, platelet reactivity, thrombus ultrastructure and thrombus kinetics one
week after NSTE-ACS.
Results: T2DMwas associatedwith increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ2/mm,
median (IQR), p = 0.045] and platelet reactivity. In addition, diabetic thrombus showed lower visco-elastic ten-
sile strength [(−0.2(−1.7 to 0.7) vs 1.0(−0.9 to 3.3), p = 0.044)] and was more resistant to autolysis
[(27.8(11.7 to 70.7) vs 78.8(68.5 to109.6) mm/min, p = 0.002)]. On SEM, fibrin fibres in diabetes were thinner,
with higher lateral interlinkage andmesh-like organisation. Thrombus quantity correlated inverselywith throm-
bus retraction (r =−0.450 p = 0.016) but not with platelet reactivity (r = 0.153, p = 0.544).
Conclusions: Despite optimal antiplatelet therapy, T2DM patients after NSTE-ACS developed increased thrombus
of lower tensile strength and slower retraction. SEM revealed loosely arrangedfibrin fibres. Our data showed sig-
nificant differences in themagnitude aswell as structural andmechanistic characteristics of thrombus in patients
with T2DM.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Patients with type 2 diabetes mellitus (T2DM) have increased car-
diovascular mortality [1,2] due to recurrent thrombotic events [2,3]. In
spite of this, current guidelines recommend similar antiplatelet and sec-
ondary prevention therapy in non-diabetic and T2DMpatients [4,5].We
have shown that blood thrombogenicity remains higher in T2DM after
non ST elevation acute coronary syndrome (NSTE-ACS) despite treat-
ment with dual antiplatelet therapy [6]. The objective of this explorato-
ry study was to evaluate the impact of T2DM on quantitative and
qualitative characteristics of thrombus after NSTE-ACS.
Methods
Studies were approved by the Local Research Ethics committee
and patients gave written informed consent. Only patients with symp-
toms of non NSTE-ACS, elevated highly sensitive cardiac troponin I
(N0.01 μmol/L) on 2 occasions, 12 hours apart and proven coronary ar-
tery disease (at least one major vessel with N50% stenosis on coronary
angiography)were included. Patientswith T2DMwere defined as either
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a) taking glucose lowering medications, b) HbA1c N6.5% and random
blood glucose N11.1 mmol/l or fasting blood glucose N7.0 mmol/l, mea-
sured on two occasions (WHOcriteria, wholibdoc.who.int/publications/
2006/9241594934_eng.pdf, accessed on 25th January 2013). All
patients were treated according to current AHA/ESC guidelines on
NSTE-ACS management including aspirin and clopidogrel [4,5]. Partici-
pants underwent whole blood thrombus and platelet reactivity studies
one week after NSTE-ACS. Thirty consecutive patients were enrolled
with 28 patients (14 T2DM) completing all studies. Two patients
were excluded because of failure to gain venous access with an
18G cannula.
i) Blood thrombogenicity using the Badimon chamber.
Briefly, the high shear chambers (inner lumen diameter 0.1 mm,
Reynolds number 60, shear rate 1690 s-1) mimic the rheologic
conditions of a moderately stenosed coronary artery, while the
low shear chamber (inner lumen diameter 0.2 mm, Reynolds
number 30, shear rate 500 s-1) simulates flow conditions of a nor-
mal coronary artery [7]. Surgically dissected porcine aorta served
as surrogate for arterial injury and native (non-anticoagulated)
blood was perfused for 5 minutes from a large antecubital vein
of the patients using 18G cannula at a rate of 10mls min-1. Two
high shear and one low shear perfusion studies were performed.
After perfusion, aorta specimens were fixed in 10% buffered
formalin and stained with modified Masson trichrome. Total
thrombus area (μ2/mm) was quantified by planimetry using a
Leica DM2000microscope (Weltzler, GmBH) under 10Xmagnifi-
cation and Image ProPlus 4.0 (Media cybernetics, MD, USA) [6,8].
Intra -observer co-efficient of variation (CV) was 4.3%.
ii) Thrombus kinetics.
The visco-elastic properties of thrombus during formation
and early phase of autolysis (thrombus retraction) were
assessed by thromboelastography (TEG®; Haemonetics
Corp, MA, USA). The time to form stable thrombus (R-time),
maximum amplitude of thrombus formation (MA), K (kinet-
ics of the rate of thrombus formation) and α (angle between
R and K) were recorded.The overall clot index (global mea-
sure of thrombus strength) was calculated (clot index =
0.6516R - 0.3772 K + 0.1224MA + 0.0759α – 7.7922).
Thrombus retraction was defined as the rate of decline in
thrombus strength from its maximum amplitude, measured
over 90 minutes (L parameter, mm/min) [9,10].
iii) Platelet reactivity.
Whole blood platelet reactivity was measured by VerifyNow®
(Accumetrics, CA, USA) using arachidonic acid reactive units
(ARU) and P2Y12 reactive units (PRU). PRUz are measured after
stimulation with adenosine diphosphate and PRUb after stimula-
tion with thrombin. We calculated percentage P2Y12 inhibition
(100X (PRUz-PRUb/PRUb). High on treatment platelet reactivity
(HOTR) to aspirin was defined as N500 ARU and to clopidogrel
as N240 PRUz [11,12].
iv) Systemic biomarkers.
Blood samples were stored at -80C after centrifuging at 1550 g for
5 minutes and thawed immediately before analysis of P-Selectin
and soluble CD40 ligand (R&D systems, UK) using sandwich
ELISA assays. Full blood count, fibrinogen, lipid levels and HbA1c
(DCCT aligned) were also analysed.
v) Scanning electron microscopy.
Thrombus generated in the chamberwas preserved in 2% glutaral-
dehyde, and then dehydrated in graded ethanol, critical-point
dried and gold-coated. Ultrastructural analysis was performed
using an S240 SEM (Cambridge Instruments, UK) on four random-
ly chosen thrombus samples (2 in each group).
vi) Statistical methods.
Statistics Data is shown as median and interquartile range for uni-
formity. Differences between groups were analysed by Mann
Whitney U test and Spearman rho test were used to test correla-
tion. Categorical data were analysed using chi square test. As
there were no published data to base power calculations, we
chose a sample size of 30 based on literature evaluating antiplate-
let therapy in T2DM using the TEG assay [13].
Results
Baseline characteristics are presented in Table 1. By virtue of selec-
tion, T2DMpatients demonstrated the typicalmetabolic syndromephe-
notype with higher triglycerides, HbA1c and systolic BP while all other
parameters were similar with the exception of lower LDL cholesterol
in T2DM.
Thrombus Quantification
T2DM was associated with increased thrombus in both high shear
and low shear conditions in the ex-vivo chamber. At high shear rate,
thrombus area (μ2/mm, interquartile range), was 14861 (8003–30161)
vs 8908 (6812–11996) for T2DM and control groups, respectively
[p = 0.045] and low shear thrombus was 10715 (6562 – 15932) v 6062
(3865–6312) [p = 0.007]. An association was seen between plasma fi-
brinogen and thrombus in the combined cohort (r 0.551, p = 0.002)
(Fig. 2). There were no significant correlations between thrombus and
HbA1c, LDL cholesterol, body mass index and diabetes duration.
Thrombus Kinetics on Thromboelastography
The time to form stable thrombus (marker of initiation of fi-
brin polymerisation) was prolonged in T2DM whilst clot index
(CI, measure of the thrombus strength) was lower [median
(inter quartile range), - 0.2(−1.7 to 0.7) vs 1.0(−0.9 to 3.3),
Table 1
Baseline characteristics.
Median (interquartile range)
or %[n]
T2DM (n = 14) Non T2DM (n = 14) P value
Demographic data:
Age, years 62 (51–68) 54 (51–63) 0.401
Male gender, 71.4 [10] 92.9 [13] 0.331
Body mass index, kg/m2 33.4(29.3-43.4) 30.6 (27.4-30.7) 0.114
Waist to hip ratio 1.0(0.9-1.0) 1.0(0.9-1.0) 0.781
Systolic BP, mmHg 134 (124–147) 120 (112–136) 0.031
Diastolic BP, mmHg 77(72–82) 72 (68–80) 0.227
Risk profile %(n):
Hypertension 64.3 [9] 21.4 [3] 0.052
Chronic Kidney Disease 21.4 [3] 7.1 [1] 0.601
Medications:
B blockers 85.7 [12] 100 [14] 0.483
Calcium channel blockers 28.6 [4] 7.1 [1] 0.331
Laboratory data:
HbA1c, % 6.6 (6.2 -8.2) 5.6 (5.3-6.1) –
Random plasma glucose, mmol/l 8.2 (6.3-11.4) 6.9 (4.9 -7.8) –
Fasting plasma glucose, mmol/l 7.3 (5.6-10.9) 5.1 (4.6-5.5) –
Haemoglobin, g/dl 13.8 (12.8-15.4) 13.7 (12.9-15.3) 0.865
Platelets, x1000/mm3 252 (191–309) 257 (209–354) 0.448
Fibrinogen, g/l 4.4 (4.1-4.6) 3.6 (2.9-4.4) 0.095
Creatinine, μmol/l 100(86–110) 99 (81–106) 0.6030
Demographic data:
Total cholesterol, mmol/l 3.2 (2.6-4.4) 3.4 (3.0-4.0) 0.667
LDLc, mmol/l 1.3 (1.0-1.7) 1.9 (1.6-2.5) 0.023
HDLc, mmol/l 0.9 (0.7-1.1) 0.9 (0.8-1.2) 0.769
Triglyceride, mmol/l 1.8 (1.4-3.4) 1.1 (0.9 -1.5) 0.002
Troponin I, μg/l 1.2 (0.1 – 10.1) 2.0 (1.1-4.1) 0.408
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p = 0.044) (Table 2). The rate of thrombus retraction, over
90 minutes (L parameter) in T2DM was slower, mm/min, [mm/
min, median (inter quartile range), 27.8(11.7 – 70.7) vs
78.8(68.5-109.6) p = 0.002)]. All other TEG parameters were
similar between groups (Table 2). Thrombus retraction or
autolysis correlated negatively with thrombus area (r =
−0.450. p = 0.016). The maximum amplitude of the thrombus
(MA) upon stimulation with kaolin correlated to platelet count
(r = 0.576, p = 0.002) and there were no correlations between
other TEG parameters and platelet reactivity indices.
Table 2
Thromboelastography and platelet reactivity indices.
Median (interquartile range) T2DM (n = 14) Non T2DM (n = 14) P value
Thrombus kinetics:
R time, min 7.3 (6.6 to 8.5) 6.6 (4.6 to 7.1) 0.021
Maximum amplitude, MA, mm 67.7 (62.0 to 70.1) 67.4 (63.8 to 74.1) 0.573
K time, min 1.8 (1.7to 2.2) 1.6 (1.2 to 2.3) 0.476
α-angle 64.5 (54.5 to 73.1) 68.6 (58.0 to 66.8) 0.306
Clot index −0.2 (−1.7 to 0.7) 1.0 (−0.9 to 3.3) 0.044
Rate of thrombus retraction (L) mm/min 27.8 (11.7 to 70.7) 78.8 (68.5 to 109.6) 0.002
Platelet Reactivity
ARU 419 (398–422) 403 (390–404) 0.623
PRUz 259 (222–311) 205 (189–232) 0.028
Percentage inhibition, % 20 (9–32) 32 (22–34) 0.083
P selectin, μg/ml 74.8 (59.3 – 77.0) 53.1 (39.7 – 68.9) 0.062
CD40 ligand, μg/ml 2934 (2046–3520) 3512 (1674–4220) 0.711
R time: Time to form a stable thrombus (min).
Maximum amplitude is the maximum strength of the formed thrombus (mm).
K time: time taken for blood to achieve 20 mm amplitude of thrombus (min).
α angle: Angle between R and the first 20 mm of amplitude tracing.
Both K value and α angle represent the speed of thrombus formation.
Clot index is a dimensionless value, representing overall thrombus strength and is derived from the formula: 0.6516R - 0.3772 K + 0.1224MA + 0.0759α – 7.7922.
Rate of thrombus retraction (L parameter) represents early phase of autolysis and is measured from the rate of decline in thrombus strength after it has reached the peak value, MA.
ARU: arachidonic acid reactive units.
PRUz: P2Y12 reactive units after stimulation with adenosine diphosphate.
Percentage inhibition: 100X (PRUz-PRUb/PRUb).
Fig. 1. Thrombus of patients from Badimon chamber (left and middle column) after staining with modified Mason trichrome. Platelet rich thrombus was stained in pink with the tunica
media of the aortic tissue stained in green. The right column shows the representative images of the thrombus under scanning electronmicroscopy (SEM) at 3.4X103 timesmagnification.
Diabetic thrombus was increased in quantity occupying a larger surface area over the tunica media. The SEM appearance showed loosely woven thrombus with thinner fibrin fibres and
mesh like appearance with less twisted arrangement compared to those without diabetes.
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Platelet Reactivity
Aspirin reactive units (ARU)were similar between groups. However,
P2Y12 reactive units were higher in T2DM [PRUZ: median (IQR) 259
(222–311) vs 205 (189–232), p = 0.028]. One patient (with T2DM)
had HOTR to aspirin whereas 13 patients [9 (64.2 %) with T2DM and 4
(28.6 %)] without had HOTR to clopidogrel. The biochemical markers
of platelet reactivity, P selectin and sCD40were similar between groups
(Table 2). There was no correlation between PRUz values and thrombus
area (rho = 0.153, p = 0.544).
Thrombus Structure on SEM
In non-T2DM, thrombus appeared organised with thick fibrin fibres
arranged longitudinally in one direction, and few side branches. In con-
trast, in patients with T2DM, thrombus appeared disorganised with
thinner fibrin fibres displaying more side-branches, giving a tangled,
mesh-like appearance (Fig. 1). The differences in thrombus structure
are displayed in Table 3.
Discussion
In this pilot study, we describe the impact of T2DM on the quantity
as well as the structural and mechanical characteristics of thrombus
after NSTE-ACS. Thromboelastography (TEG®) [9,13], showed that the
visco-elastic property of whole blood and thrombus strength (fibrin-
platelet binding) during thrombogenesis and autolysis was different in
T2DM.
We observed that thrombus in T2DM was larger and more stable,
but slower to undergo lysis. Studies undertaken with the perfusion
chamber revealed increased thrombus both at high and low local
shear rate conditions in T2DM patients. The most striking difference in
thrombus kinetics was an approximately three fold slower rate of clot
retraction in diabetic participants. The time to form stable clot was
also increased whilst clot index (a measure of strength) was decreased.
Of interest, the observations on the different structural and kinetic char-
acteristics of the thrombus have not been previously reported in whole
blood testing. The rate of thrombus retractionwas negatively correlated
to thrombus quantity in this studywhich suggests that thrombus, in ad-
dition to being higher in quantity, also persists longer after initial forma-
tion. In vivo, persistence of thrombus would provide a nidus for more
thrombus formation and this may lead to a pathophysiological cycle of
‘thrombus begetting thrombus’ in patients with T2DM. Although in-
vitro studies show impaired fibrinolyis (later phase of autolyis) in
T2DM [14], little is known of thrombus retraction which represents
the early phase of autolyis.
SEM analysis of the thrombus (qualitative analysis) as an explorato-
ry pilot study illustrated some important ultrastructural characteristics
further explaining these findings. In the early stages of thrombogenesis
(5 minutes of Badimon chamber study), thrombus in T2DM was com-
posed of less compact and loosely arranged fibrin to fibrin structure.
Scanning electron microscopy of thrombus revealed a markedly differ-
ent architecture between the diabetic and non-diabetic patients. Earlier
studies using reconstituted plasma have shown altered fibrin structure
in patients with T2DM, with reduced elasticity [15]. Alterations in fibrin
structure in patients with T2DM have been attributed to non enzymatic
glycation of fibrinogen. Glycated fibrinogen enhances thrombogenicity
by increasing fibrin polymerisation and cross-linking, reducing tissue
plasminogen activator and plasminogen binding, and slowing plasmin-
ogen to plasmin conversion [16]. This arrangement of the fibrin fibres
was similar to that seen in our study using whole blood in a surrogate
model of plaque rupture.
Findings from thromboelastography and SEM are complementary
and the differing ultrastructural characteristics may in part explain the
differences in thrombus kinetics seen on TEG®. Thrombus in T2DM
had thinner fibrin fibres, with more lateral aggregations, occurring in a
disorganised, tangled or web-like fashion. This may favour propagation
of thrombus by trapping more cellular elements, and in addition, may
make clot retraction and degradation more difficult. Thus the increased
thrombus quantity in T2DM may be due to both increased blood
thrombogenicity generating larger thrombus and decreased degrada-
tion. The presence of thinner fibrin fibres in T2DMmay result in lower
visco-elastic strength of diabetic thrombus and could be one explana-
tion for the differences seen on TEG® [17]. The finding of loosely
bound but persistent thrombus in diabetes may increase the potential
for embolisation to distal arteries resulting in increased end organ dam-
age. In addition, a less compact and loosely bound fibrin fibre arrange-
ment is a marker of poor fibrinolysis [18]. Presence of less longitudinal
twisting in T2DM could result in lower visco elastic strength of diabetic
thrombus and can thus explain the differences seen in TEG® studies
[19].
T2DM is a prothrombotic state associated with HOTR [14,20]. More
patients with T2DM had HOTR with VerifyNow®, findings similar to
the main study. More patients with T2DM had HOTR consistent with
earlier reports [21,22]. In our small cohort of patients on optimal sec-
ondary prevention therapy there were no differences in other indirect
measures of platelet reactivity (plasma fibrinogen, P selectin and solu-
ble CD40 ligand) in those with and without diabetes. Platelet counts
showed an association to MA in our study implying a significant contri-
bution of platelets to the viscoelastic property of thrombus. Again, we
did not observe any correlation between VerifyNow® indices and
thrombus area, a finding we have previously reported in a population
Fig. 2. Correlation graphs between thrombus area and various parameters. Correlation
analysis: a. Serum fibrinogen correlated with thrombus area, r = 0.551, p = 0.002.
b. Thrombus retraction or autolysis correlatedwith thrombus area, r=−0.450. p= 0.016.
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with stable coronary artery disease [6]. The standard TEG indices did not
show any correlation to thrombus either. The negative finding of unal-
tered kaolin stimulated TEG® parameters (standard TEG®) after aspirin
and clopidogrel therapy is not surprising. Kaolin stimulates
thrombogenesis via the powerful pro-coagulant thrombin, which acts
in the final common pathway bypassing the effects of ADP on coagula-
tion cascade. The results could have been different if platelet mapping
algorithm was used, which measures effects of individual platelet
agonists like ADP and archidonic acid [23]. The consistent lack of corre-
lation between platelet reactivity and thrombus area suggest that point
of care measure of platelet reactivity does not reflect whole blood
thrombogenicity which is a complex pathophysiology involving other
factors in addition to platelets. Our results may in part explain the neg-
ative results of the GRAVITAS and ARCTIC studies using VerifyNow®
[24,25].
Our findings provide additional mechanistic support for the propos-
al that ‘perpetuation and propagation of diabetic thrombus’, with a
pathophysiological cycle of “thrombus begets thrombus”, is responsible
for increased recurrent acute coronary events in T2DM patients [26]. It
is known that patients with T2DM have ‘vulnerable blood’ which is re-
sponsible for moremajor adverse cardiovascular events after NSTE-ACS
[27].There are no published studies of differences in the visco-elastic
properties and fibrin structure of thrombus in patients with and
without T2DM after NSTE-ACS. It is possible that loosely bound diabetic
thrombus which is higher in quantity may also embolise easily to distal
arteries. Nevertheless, once formed, the diabetic thrombus was slower
to undergo clot retraction (early autolysis) and along with the well
known defects in fibrinolysis (late autolysis), these findings support
the view that ‘perpetuation and propagation of diabetic thrombus’ is re-
sponsible for recurrent acute coronary events [28]. Thus our findings, in
a small cohort, are novel, hypothesis generating and require further
validation.
By using whole blood testing we have reported a comprehensive
evaluation of thrombotic potential in patients with T2DM. These find-
ings provide mechanistic insight into the higher risk of thrombotic
events seen in T2DM patients in contemporary studies [29,30]. The
differences seen in the ultrastructure and mechanistic properties of
thrombus provide a focus for further studies that may lead to novel
pharmacological treatments targeting the fibrin pathway.
There are significant limitations in our study. Our cohort is small and
the generalisablity of our findings needs to be confirmed. However, our
subjects were carefully selected to maintain homogeneity of patient
characteristics. Our findings are descriptive in nature and therefore
need to be confirmed by experimental and interventional studies. We
studied aspirin and clopidogrel in our study and the effects of newer
antiplatelet agents on thrombus structure and viscoelastic property in
T2DM remain unknown.
Conclusion
In patients with T2DM after NSTE-ACS, we found increased
thrombus which was slower to undergo autolysis, with altered fibrin
architecture. The combination of increased quantity and persistence of
thrombus may explain the “vulnerable blood” and higher thromboem-
bolic events in T2DM after NSTE-ACS. The differences seen in the ultra-
structure and mechanistic properties of thrombus provide a focus for
further studies that may lead to novel pharmacological treatments in
the diabetic patients.
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